HDAC inhibitor could sensitize rituximab‐resistant DLBCL cells by upregulating CD20 expression through promoting CD20 promoter acetylation and Sp1 recruitment [29]. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.